← Leaderboards
Allan D. Kirk
Emory University
$41,350,860
Attributed
$46,382,577
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,565,193 · 16
FDA$3,817,384 · 1
By mechanism
U01$26,614,688 · 4
U19$10,945,603 · 5
R01$6,413,752 · 2
T32$1,874,466 · 2
R56$402,500 · 1
P51$131,568 · 3
Top collaborators
- Kent J. Weinhold6 shared
- Xunrong Luo5 shared
- Aravind Asokan4 shared
- Andrew Serghios Barbas4 shared
- Linda Cendales-Behaine1 shared
- Jean Kwun1 shared
- Georgia D Tomaras1 shared
Most similar at Emory University
Same institution · by research overlap
- A Joseph Tector$7,587,844
- Allan I Levey$89,469,218
- Christian P Larsen$35,318,088
- Thomas C Pearson$2,137,465
- Andrew B Adams$22,168,263
Others in their field
Top investigators on “Transplantation”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Mary M Horowitz · Medical College Of Wisconsin$224,924,548
- Craig B Thompson · Sloan-Kettering Inst Can Research$157,997,949
- Charles A Coltman · Southwest Oncology Group$141,983,231
- Richard L Schilsky · University Of Chicago$117,759,216
- Harold E Varmus · Sloan-Kettering Institute For Cancer Res$82,854,111
Research focus
TransplantationImmunePreventRegimenBaseImmunosuppressive AgentsPhenotypeViralOrganKidney TransplantationAllograftingNonhuman PrimateCellsCharacteristicsImmunoregulationResponseT-LymphocyteAntigensCd28 GeneOrgan TransplantationMediatingClinically RelevantKidneyClinical Trials
Grant awards (75)
Computational Immunobiology Core$926,302
U19 · FY2025 · AI · contact PI
Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectors$469,775
U01 · FY2025 · AI
Advanced Immunobiology Traning Program for Surgeons$281,722
T32 · FY2025 · AI · contact PI
Neonatal porcine islet xenografts for the treatment of type 1 diabetes$1,090,894
U01 · FY2024 · AI · contact PI
Computational Immunobiology Core$790,915
U19 · FY2024 · AI · contact PI
Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectors$473,435
U01 · FY2024 · AI
The impact of targeting CD40-CD154 pathway in nonhuman primate vascularized composite allograft model$402,500
R56 · FY2024 · AI
Advanced Immunobiology Traning Program for Surgeons$282,004
T32 · FY2024 · AI · contact PI
Neonatal porcine islet xenografts for the treatment of type 1 diabetes$1,090,894
U01 · FY2023 · AI · contact PI
Computational Immunobiology Core$827,611
U19 · FY2023 · AI · contact PI
Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectors$477,093
U01 · FY2023 · AI
Advanced Immunobiology Traning Program for Surgeons$254,218
T32 · FY2023 · AI · contact PI
Neonatal porcine islet xenografts for the treatment of type 1 diabetes$1,090,894
U01 · FY2022 · AI · contact PI
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients$657,458
U19 · FY2022 · AI · contact PI
Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectors$483,000
U01 · FY2022 · AI
Advanced Immunobiology Traning Program for Surgeons$262,411
T32 · FY2022 · AI · contact PI
Neonatal porcine islet xenografts for the treatment of type 1 diabetes$1,090,894
U01 · FY2021 · AI · contact PI
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients$854,803
U19 · FY2021 · AI · contact PI
Advanced Immunobiology Traning Program for Surgeons$245,499
T32 · FY2021 · AI · contact PI
Neonatal porcine islet xenografts for the treatment of type 1 diabetes$1,070,151
U01 · FY2020 · AI · contact PI
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients$974,213
U19 · FY2020 · AI · contact PI
Advanced Immunobiology Traning Program for Surgeons$157,330
T32 · FY2020 · AI · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$936,759
U01 · FY2019 · AI · contact PI
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients$842,067
U19 · FY2019 · AI · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$357,108
R01 · FY2019 · FD · contact PI
Advanced Immunobiology Traning Program for Surgeons$72,119
T32 · FY2019 · AI · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$940,355
U01 · FY2018 · AI · contact PI
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients$769,507
U19 · FY2018 · AI · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$371,377
R01 · FY2018 · FD · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$943,871
U01 · FY2017 · AI · contact PI
Depletion, Repopulation and Tolerance in Non-Sensitied Recipients$733,286
U19 · FY2017 · AI · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$380,418
R01 · FY2017 · FD · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$947,320
U01 · FY2016 · AI · contact PI
Cell Adhesion and Trafficking as a Therapeutic Target in Allotransplantation$836,674
U19 · FY2016 · AI · contact PI
T Cell Maturation and the Nexus of Viral- and Allo-Immunity$533,151
R01 · FY2016 · AI · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$400,000
R01 · FY2016 · FD · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$951,202
U01 · FY2015 · AI · contact PI
T Cell Maturation and the Nexus of Viral- and Allo-Immunity$532,597
R01 · FY2015 · AI · contact PI
Cell Adhesion and Trafficking as a Therapeutic Target in Allotransplantation$499,758
U19 · FY2015 · AI · contact PI
Cell Adhesion and Trafficking as a Therapeutic Target in Allotransplantation$925,328
U19 · FY2014 · AI · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$915,867
U01 · FY2014 · AI · contact PI
T Cell Maturation and the Nexus of Viral- and Allo-Immunity$438,707
R01 · FY2014 · AI · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$895,418
U01 · FY2013 · AI · contact PI
Cell Adhesion and Trafficking as a Therapeutic Target in Allotransplantation$714,806
U19 · FY2013 · AI · contact PI
T Cell Maturation and the Nexus of Viral- and Allo-Immunity$548,675
R01 · FY2013 · AI · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$286,307
R01 · FY2013 · FD · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$248,134
R01 · FY2013 · FD · contact PI
Advanced Research Training in Transplantation Science$179,047
T32 · FY2013 · AI · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$113,693
R01 · FY2013 · FD · contact PI
T Cell Maturation and the Nexus of Viral- and Allo-Immunity$20,980
R01 · FY2013 · AI · contact PI
Development of Transplant Strategies Uniquely Responsive to the Needs of Children$1,017,454
U01 · FY2012 · AI · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$934,584
U01 · FY2012 · AI · contact PI
Adjuvant Therapies Improving the Anti-Rejection Effects of Costimulation Blockade$606,945
U01 · FY2012 · AI · contact PI
Cell Adhesion and Trafficking as a Therapeutic Target in Allotransplantation$592,875
U19 · FY2012 · AI · contact PI
T Cell Maturation and the Nexus of Viral- and Allo-Immunity$522,258
R01 · FY2012 · AI · contact PI
Phase 2 Study of Belatacept, Alemtuzumab, and Sirolimus in Renal Transplantation$151,866
R01 · FY2012 · FD · contact PI
Advanced Research Training in Transplantation Science$140,116
T32 · FY2012 · AI · contact PI
Development of Transplant Strategies Uniquely Responsive to the Needs of Children$1,490,083
U01 · FY2011 · AI · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$958,318
U01 · FY2011 · AI · contact PI
Adjuvant Therapies Improving the Anti-Rejection Effects of Costimulation Blockade$607,239
U01 · FY2011 · AI · contact PI
A PHASE 2 TOLERANCE TRIAL OF BELATACEPT AND ALEMTUZUMAB IN RENAL TRANSPLANTATION$392,536
R01 · FY2011 · FD · contact PI
ADJUVANT THERAPIES IMPROVING ANTI-REJECTION EFFECTS OF COSTIMULATION BLOCKADE$32,906
P51 · FY2011 · RR · contact PI
Development of Transplant Strategies Uniquely Responsive to the Needs of Children$1,025,475
U01 · FY2010 · AI · contact PI
Neonatal Porcine Islet Xenografts for the Treatment of Type 1 Diabetes$966,935
U01 · FY2010 · AI · contact PI
Adjuvant Therapies Improving the Anti-Rejection Effects of Costimulation Blockade$613,352
U01 · FY2010 · AI · contact PI
A PHASE 2 TOLERANCE TRIAL OF BELATACEPT AND ALEMTUZUMAB IN RENAL TRANSPLANTATION$382,057
R01 · FY2010 · FD · contact PI
Development of Transplant Strategies Uniquely Responsive to the Needs of Children$78,517
U01 · FY2010 · AI · contact PI
ADJUVANT THERAPIES IMPROVING ANTI-REJECTION EFFECTS OF COSTIMULATION BLOCKADE$43,862
P51 · FY2010 · RR · contact PI
Development of Transplant Strategies Uniquely Responsive to the Needs of Children$1,649,526
U01 · FY2009 · AI · contact PI
Development of Transplant Strategies Uniquely Responsive to the Needs of Children$1,007,528
U01 · FY2009 · AI · contact PI
Adjuvant Therapies Improving the Anti-Rejection Effects of Costimulation Blockade$603,999
U01 · FY2009 · AI · contact PI
A PHASE 2 TOLERANCE TRIAL OF BELATACEPT AND ALEMTUZUMAB IN RENAL TRANSPLANTATION$371,883
R01 · FY2009 · FD · contact PI
NPH RENAL & SKIN TRANSPLANTATION FOR ALLOSPECIFIC TOLERANCE INDUCTION$54,800
P51 · FY2009 · RR · contact PI
Development of Transplant Strategies Uniquely Responsive to the Needs of Children$1,186,911
U01 · FY2008 · AI · contact PI
A PHASE 2 TOLERANCE TRIAL OF BELATACEPT AND ALEMTUZUMAB IN RENAL TRANSPLANTATION$362,005
R01 · FY2008 · FD · contact PI